JP2008540629A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2008540629A5 JP2008540629A5 JP2008511809A JP2008511809A JP2008540629A5 JP 2008540629 A5 JP2008540629 A5 JP 2008540629A5 JP 2008511809 A JP2008511809 A JP 2008511809A JP 2008511809 A JP2008511809 A JP 2008511809A JP 2008540629 A5 JP2008540629 A5 JP 2008540629A5
- Authority
- JP
- Japan
- Prior art keywords
- compound
- composition
- matrix
- cellulose acetate
- hydroxypropylmethylcellulose
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 239000000203 mixture Substances 0.000 claims 25
- 150000001875 compounds Chemical class 0.000 claims 16
- 239000011159 matrix material Substances 0.000 claims 10
- 239000008194 pharmaceutical composition Substances 0.000 claims 8
- 229940126062 Compound A Drugs 0.000 claims 6
- NLDMNSXOCDLTTB-UHFFFAOYSA-N Heterophylliin A Natural products O1C2COC(=O)C3=CC(O)=C(O)C(O)=C3C3=C(O)C(O)=C(O)C=C3C(=O)OC2C(OC(=O)C=2C=C(O)C(O)=C(O)C=2)C(O)C1OC(=O)C1=CC(O)=C(O)C(O)=C1 NLDMNSXOCDLTTB-UHFFFAOYSA-N 0.000 claims 6
- 229920002301 cellulose acetate Polymers 0.000 claims 6
- 150000003839 salts Chemical class 0.000 claims 6
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 claims 5
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 claims 5
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 claims 5
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 claims 5
- 238000000034 method Methods 0.000 claims 5
- 239000012453 solvate Substances 0.000 claims 5
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 claims 4
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 claims 4
- GAMPNQJDUFQVQO-UHFFFAOYSA-N acetic acid;phthalic acid Chemical compound CC(O)=O.OC(=O)C1=CC=CC=C1C(O)=O GAMPNQJDUFQVQO-UHFFFAOYSA-N 0.000 claims 4
- 239000001863 hydroxypropyl cellulose Substances 0.000 claims 4
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 claims 4
- 229920000623 Cellulose acetate phthalate Polymers 0.000 claims 3
- 239000004372 Polyvinyl alcohol Substances 0.000 claims 3
- 150000001732 carboxylic acid derivatives Chemical class 0.000 claims 3
- 229940081734 cellulose acetate phthalate Drugs 0.000 claims 3
- 229920000609 methyl cellulose Polymers 0.000 claims 3
- 239000001923 methylcellulose Substances 0.000 claims 3
- 235000010981 methylcellulose Nutrition 0.000 claims 3
- -1 polyethylene Polymers 0.000 claims 3
- 229920002451 polyvinyl alcohol Polymers 0.000 claims 3
- 239000007921 spray Substances 0.000 claims 3
- 229920000663 Hydroxyethyl cellulose Polymers 0.000 claims 2
- 239000004354 Hydroxyethyl cellulose Substances 0.000 claims 2
- 229920001479 Hydroxyethyl methyl cellulose Polymers 0.000 claims 2
- 241000124008 Mammalia Species 0.000 claims 2
- ZNPLZHBZUSCANM-UHFFFAOYSA-N acetic acid;benzene-1,3-dicarboxylic acid Chemical compound CC(O)=O.OC(=O)C1=CC=CC(C(O)=O)=C1 ZNPLZHBZUSCANM-UHFFFAOYSA-N 0.000 claims 2
- FMTQGBMMIVVKSN-UHFFFAOYSA-N acetic acid;terephthalic acid Chemical compound CC(O)=O.OC(=O)C1=CC=C(C(O)=O)C=C1 FMTQGBMMIVVKSN-UHFFFAOYSA-N 0.000 claims 2
- 150000001412 amines Chemical class 0.000 claims 2
- 239000006185 dispersion Substances 0.000 claims 2
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 2
- 235000019447 hydroxyethyl cellulose Nutrition 0.000 claims 2
- 229920003132 hydroxypropyl methylcellulose phthalate Polymers 0.000 claims 2
- 229940031704 hydroxypropyl methylcellulose phthalate Drugs 0.000 claims 2
- 229920000639 hydroxypropylmethylcellulose acetate succinate Polymers 0.000 claims 2
- 238000001727 in vivo Methods 0.000 claims 2
- 125000003356 phenylsulfanyl group Chemical group [*]SC1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 claims 2
- 229920000058 polyacrylate Polymers 0.000 claims 2
- 229920000193 polymethacrylate Polymers 0.000 claims 2
- 210000002966 serum Anatomy 0.000 claims 2
- 239000007787 solid Substances 0.000 claims 2
- 239000002904 solvent Substances 0.000 claims 2
- 125000005591 trimellitate group Chemical group 0.000 claims 2
- 229920006163 vinyl copolymer Polymers 0.000 claims 2
- GAWIXWVDTYZWAW-UHFFFAOYSA-N C[CH]O Chemical group C[CH]O GAWIXWVDTYZWAW-UHFFFAOYSA-N 0.000 claims 1
- 239000001856 Ethyl cellulose Substances 0.000 claims 1
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 claims 1
- 239000004698 Polyethylene Substances 0.000 claims 1
- 239000002202 Polyethylene glycol Substances 0.000 claims 1
- 229920002472 Starch Polymers 0.000 claims 1
- 230000002159 abnormal effect Effects 0.000 claims 1
- 125000000217 alkyl group Chemical group 0.000 claims 1
- 125000003118 aryl group Chemical group 0.000 claims 1
- 229920001400 block copolymer Polymers 0.000 claims 1
- 230000010261 cell growth Effects 0.000 claims 1
- 150000003950 cyclic amides Chemical class 0.000 claims 1
- 229920001249 ethyl cellulose Polymers 0.000 claims 1
- 235000019325 ethyl cellulose Nutrition 0.000 claims 1
- 238000001704 evaporation Methods 0.000 claims 1
- 230000002209 hydrophobic effect Effects 0.000 claims 1
- 229920013819 hydroxyethyl ethylcellulose Polymers 0.000 claims 1
- 238000000338 in vitro Methods 0.000 claims 1
- 239000007788 liquid Substances 0.000 claims 1
- 229960002900 methylcellulose Drugs 0.000 claims 1
- 229920000573 polyethylene Polymers 0.000 claims 1
- 229920001223 polyethylene glycol Polymers 0.000 claims 1
- 229920002503 polyoxyethylene-polyoxypropylene Polymers 0.000 claims 1
- 229920001451 polypropylene glycol Polymers 0.000 claims 1
- 229920002689 polyvinyl acetate Polymers 0.000 claims 1
- 239000011118 polyvinyl acetate Substances 0.000 claims 1
- 102000004169 proteins and genes Human genes 0.000 claims 1
- 108090000623 proteins and genes Proteins 0.000 claims 1
- HNJBEVLQSNELDL-UHFFFAOYSA-N pyrrolidin-2-one Chemical compound O=C1CCCN1 HNJBEVLQSNELDL-UHFFFAOYSA-N 0.000 claims 1
- 239000008107 starch Substances 0.000 claims 1
- 235000019698 starch Nutrition 0.000 claims 1
- 125000001424 substituent group Chemical group 0.000 claims 1
- 229920002554 vinyl polymer Polymers 0.000 claims 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US68292805P | 2005-05-19 | 2005-05-19 | |
| PCT/IB2006/001295 WO2006123223A1 (en) | 2005-05-19 | 2006-05-08 | Pharmaceutical compostions comprising an amorphous form of a vegf-r inhibitor |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2008540629A JP2008540629A (ja) | 2008-11-20 |
| JP2008540629A5 true JP2008540629A5 (enExample) | 2009-01-08 |
Family
ID=36933392
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2008511809A Withdrawn JP2008540629A (ja) | 2005-05-19 | 2006-05-08 | 非晶形のｖｅｇｆ−ｒ阻害剤を含む医薬組成物 |
Country Status (5)
| Country | Link |
|---|---|
| US (1) | US20080274192A1 (enExample) |
| EP (1) | EP1885338A1 (enExample) |
| JP (1) | JP2008540629A (enExample) |
| CA (1) | CA2608952A1 (enExample) |
| WO (1) | WO2006123223A1 (enExample) |
Families Citing this family (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20070058690A (ko) | 2004-11-02 | 2007-06-08 | 화이자 인코포레이티드 | 인다졸 화합물의 제조방법 |
| MX2009010761A (es) † | 2007-04-05 | 2009-10-28 | Pfizer Prod Inc | Formas cristalinas de 6-[2-(metilcarbamoil)fenilsulfanil]-3-e-[2-( piridin-2-il)etenil]indzol adecuadas para el tratamiento del crecimiento celular anormal en mamiferos. |
| EP2305263B1 (en) * | 2007-06-07 | 2012-09-19 | Novartis AG | Stabilized amorphous forms of imatinib mesylate |
| SG174488A1 (en) * | 2009-03-19 | 2011-10-28 | Shionogi & Co | Solid preparation containing npy y5 receptor antagonist |
| WO2012042421A1 (en) | 2010-09-29 | 2012-04-05 | Pfizer Inc. | Method of treating abnormal cell growth |
| MX2014003886A (es) | 2011-09-30 | 2014-05-13 | Pfizer | Composiciones farmaceuticas de n-metil-2-[3-((e) 2-piridin-2-il-vinil)-1h-indazol-6-ilsulfanil]benzamida. |
| WO2013068909A1 (en) | 2011-11-11 | 2013-05-16 | Pfizer Inc. | N-methyl-2-[3-((e)-2-pyridin-2-yl-vinyl)-1h-indazol-6-ylsulfanyl]-benzamide for the treatment of chronic myelogenous leukemia |
| ES2946549T3 (es) | 2012-01-13 | 2023-07-20 | Xspray Pharma Ab Publ | Composición farmacéutica de nilotinib |
| EP4450130A3 (en) * | 2012-09-11 | 2025-01-08 | Medivation Prostate Therapeutics LLC | Formulations of enzalutamide |
| EP2956121B1 (en) * | 2013-02-12 | 2018-05-30 | Bend Research, Inc. | Solid dispersions of low-water solubility actives |
| EP2792360A1 (en) | 2013-04-18 | 2014-10-22 | IP Gesellschaft für Management mbH | (1aR,12bS)-8-cyclohexyl-11-fluoro-N-((1-methylcyclopropyl)sulfonyl)-1a-((3-methyl-3,8-diazabicyclo[3.2.1]oct-8-yl)carbonyl)-1,1a,2,2b-tetrahydrocyclopropa[d]indolo[2,1-a][2]benzazepine-5-carboxamide for use in treating HCV |
| CN104140414B (zh) * | 2013-05-07 | 2018-12-11 | 江苏豪森药业集团有限公司 | 阿昔替尼晶型的制备方法 |
| WO2015067224A1 (en) | 2013-11-08 | 2015-05-14 | Zentiva, K.S. | Salts of 6-[2-(methylcarbamoyl)phenylsulfanyl]-3-e-[2-(pyridin-2-yl)ethanyl] indazole |
| CA2929499C (en) * | 2013-11-22 | 2019-01-08 | Merck Sharp & Dohme Corp. | Composition of a non-nucleoside reverse transcriptase inhibitor |
| CN118286440A (zh) | 2014-02-04 | 2024-07-05 | 辉瑞大药厂 | 用于治疗癌症的pd-1拮抗剂和vegfr抑制剂的组合 |
| JP2017530950A (ja) | 2014-08-25 | 2017-10-19 | ファイザー・インコーポレイテッド | 癌を処置するためのｐｄ−１アンタゴニストおよびａｌｋ阻害剤の併用 |
| IL278423B2 (en) | 2015-02-26 | 2024-04-01 | Merck Patent Gmbh | Pd-1 / pd-l1 inhibitors for the treatment of cancer |
| KR102013440B1 (ko) * | 2015-04-03 | 2019-08-22 | 임팩트 테라퓨틱스, 인코포레이티드 | Parp 억제제 고체약물제형 및 그 용도 |
| RU2766890C2 (ru) | 2015-06-16 | 2022-03-16 | Мерк Патент Гмбх | Комбинированные способы лечения антагонистами pd-l1 |
| CN106467512B (zh) * | 2015-08-19 | 2022-03-11 | 浙江九洲药业股份有限公司 | 一种阿西替尼富马酸盐及其结晶形式和制备方法 |
| CA3039451A1 (en) | 2016-10-06 | 2018-04-12 | Pfizer Inc. | Dosing regimen of avelumab for the treatment of cancer |
| WO2019234581A1 (en) * | 2018-06-04 | 2019-12-12 | Glenmark Pharmaceuticals Limited | Pharmaceutical compositions of axitinib |
| US20220370606A1 (en) | 2018-12-21 | 2022-11-24 | Pfizer Inc. | Combination Treatments Of Cancer Comprising A TLR Agonist |
| WO2022000265A1 (zh) * | 2020-06-30 | 2022-01-06 | 天津理工大学 | 一种阿西替尼与戊二酸共晶及其制备方法 |
| JP7654346B2 (ja) | 2022-03-03 | 2025-04-01 | ファイザー・インク | 多重特異性抗体およびその使用 |
| WO2025157389A1 (en) | 2024-01-22 | 2025-07-31 | Iomx Therapeutics Ag | Combinations of halogenated heterocyclic kinase inhibitors and vegfr inhibitors |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS53148542A (en) * | 1977-05-27 | 1978-12-25 | Reiichi Yamaga | Pharmaceutical composition densistry |
| JPS59219384A (ja) * | 1983-05-30 | 1984-12-10 | Mitsui Norin Kk | 天然抗酸化剤の製造方法 |
| US5266319A (en) * | 1992-03-18 | 1993-11-30 | National Science Council | Tannin derivatives and their use for treatment of hypertension |
| US5773419A (en) * | 1995-03-03 | 1998-06-30 | Falcon; Juan | Method of treating cancer with tannic acid |
| US6350786B1 (en) * | 1998-09-22 | 2002-02-26 | Hoffmann-La Roche Inc. | Stable complexes of poorly soluble compounds in ionic polymers |
| US6706283B1 (en) * | 1999-02-10 | 2004-03-16 | Pfizer Inc | Controlled release by extrusion of solid amorphous dispersions of drugs |
| TWI262914B (en) * | 1999-07-02 | 2006-10-01 | Agouron Pharma | Compounds and pharmaceutical compositions for inhibiting protein kinases |
| PE20010306A1 (es) * | 1999-07-02 | 2001-03-29 | Agouron Pharma | Compuestos de indazol y composiciones farmaceuticas que los contienen utiles para la inhibicion de proteina kinasa |
| EP1120109A3 (en) * | 2000-01-24 | 2002-07-10 | Pfizer Products Inc. | Rapidly disintegrating and fast dissolving solid dosage form |
| PT1469833T (pt) * | 2002-02-01 | 2021-07-13 | Bend Res Inc | Método para produzir dispersões de fármaco amorfo sólido seco por pulverização homogéneas utilizando aparelho de secagem por pulverização modificado |
| US20040126448A1 (en) * | 2002-08-05 | 2004-07-01 | Nils-Olof Lindberg | Sexual dysfunction compounds |
| WO2004092217A1 (en) * | 2003-04-17 | 2004-10-28 | Pfizer Inc. | Crystal structure of vegfrkd: ligand complexes and methods of use thereof |
| AU2005300317A1 (en) * | 2004-11-02 | 2006-05-11 | Pfizer Inc. | Polymorphic forms of 6-[2-(methylcarbamoyl)phenylsulfanyl]-3-E-[2-(pyridin-2-yl)ethenyl]indazole |
-
2006
- 2006-05-08 US US11/914,289 patent/US20080274192A1/en not_active Abandoned
- 2006-05-08 EP EP06744719A patent/EP1885338A1/en not_active Withdrawn
- 2006-05-08 JP JP2008511809A patent/JP2008540629A/ja not_active Withdrawn
- 2006-05-08 WO PCT/IB2006/001295 patent/WO2006123223A1/en not_active Ceased
- 2006-05-08 CA CA002608952A patent/CA2608952A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2008540629A5 (enExample) | ||
| AU2005324132B2 (en) | Solid, orally applicable pharmaceutical administration forms containing rivaroxaban having modified release | |
| KR102639753B1 (ko) | 난수용성 화합물용 약제학적 조성물 | |
| EP2982367A1 (en) | Pharmaceutical composition for parenteral administration, containing donepezil | |
| CN102316867B (zh) | 氨氯地平微球制剂、其制备方法及应用 | |
| KR101689688B1 (ko) | ２옥소１피롤리딘 유도체를 포함하는 지연 방출형 제형 | |
| WO2013179307A2 (en) | Stabilized pharmaceutical compositions of saxagliptin | |
| MX2007010889A (es) | Formulaciones farmaceuticas gastrorresistentes que contienen rifaximina. | |
| WO2021196734A1 (zh) | 一种布立西坦控释制剂及其制备方法 | |
| KR20140019038A (ko) | 양호한 수용해도를 가지는 활성 성분을 위한 활성 성분 전달이 제어되는 제약 조성물 | |
| CN103118666A (zh) | 含有利福昔明的药物制剂、制备其的方法和治疗肠疾病的方法 | |
| KR20160115995A (ko) | 지속 방출 특성을 가지며 에탄올의 영향에 대한 저항성을 갖는 약제학적 또는 건강기능성 조성물 | |
| CN102548543B (zh) | 具有改进的溶出率和最小的副作用的缓释的西洛他唑片剂 | |
| CN105232489B (zh) | 一种阿利沙坦酯固体分散体及含有该固体分散体的药物组合物 | |
| US20230048354A1 (en) | Dosage form for use in treating or preventing of a disease | |
| EP2533766B1 (en) | Pharmaceutical mini-tablets for sustained release of flecainide acetate | |
| WO2014060561A1 (en) | Oral pharmaceutical formulations comprising dabigatran | |
| JP2010536837A5 (enExample) | ||
| CN112107559A (zh) | 口腔透粘膜药物剂型 | |
| EP4072532B1 (en) | Dosage form for use in treating or preventing of a disease | |
| EP2471521B1 (en) | Double-layer osmotic pump controlled release tablet of bicyclol and preparation method thereof | |
| CN101478958A (zh) | 包含哌啶烷醇和减充血剂的组合的药物组合物 | |
| WO2018229784A1 (en) | Pharmaceutical compositions of dabigatran | |
| WO2024220974A1 (en) | Rimegepant fast-dissolving films for oral administration | |
| CN103845332B (zh) | 一种达沙替尼药用组合物及其制备方法 |